5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.
Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT3 receptor antagonist ondansetron (16 mg PO) in 11 physically healthy male volunteers. Compared to pretreatment with placebo, pre-treatment with ondansetron did not significantly attenuate the PRL response to d-FEN challenge. These data are consistent with other data suggesting little role for 5-HT3 receptors in the PRL response to 5-HT agonist challenge in human subjects.
Coccaro
E F
EF
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia 19129, USA.
Kavoussi
R J
RJ
Cooper
T B
TB
Hauger
R
R
D000328:Adult; D005277:Fenfluramine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*
D005277:Fenfluramine; D017294:Ondansetron; D011388:Prolactin; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors